

Chantana Polprasert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/932869/publications.pdf>

Version: 2024-02-01

26
papers

953
citations

1163117

8
h-index

752698

20
g-index

28
all docs

28
docs citations

28
times ranked

1693
citing authors

#	ARTICLE	IF	CITATIONS
1	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	30.7	372
2	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. <i>Cancer Cell</i> , 2015, 27, 658-670.	16.8	341
3	Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 588-595.	5.2	73
4	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	10.7	46
5	Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance. <i>Acta Haematologica</i> , 2020, 143, 78-88.	1.4	21
6	Novel DDX41 variants in Thai patients with myeloid neoplasms. <i>International Journal of Hematology</i> , 2020, 111, 241-246.	1.6	20
7	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 95-103.	1.3	12
8	Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients.. <i>Hematology Reports</i> , 2019, 11, 8183.	0.8	10
9	A Randomized Multicenter Trial Comparing Low-Dose Prednisolone Versus Observation for Prevention of Recurrences in Adult Immune Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 867-873.	1.7	8
10	Cold agglutinin disease following SARS-CoV-2 and <i>Mycoplasma pneumoniae</i> infections. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2402-2405.	0.5	8
11	Case report: severe CMV colitis in a patient with follicular lymphoma after chemotherapy. <i>Journal of the Medical Association of Thailand = Chotmaihet Thangphaet</i> , 2011, 94, 498-500.	0.1	8
12	Clinical Impacts of Germline <i>DDX41</i> Mutations on Myeloid Neoplasms. <i>Blood</i> , 2020, 136, 38-40.	1.4	7
13	Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e509-e514.	0.4	6
14	Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages. <i>Haemophilia</i> , 2021, 27, e155-e159.	2.1	5
15	Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e635-e643.	0.4	3
16	Better survivals in adolescent and Young adults, compared to adults with acute lymphoblastic leukemia – A multicenter prospective registry in Thai population. <i>Leukemia Research</i> , 2019, 87, 106235.	0.8	2
17	Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunction in women with hematological malignancies. <i>Hematology</i> , 2022, 27, 181-186.	1.5	2
18	Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e915-e921.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Genetic mutations associated with blood count abnormalities in myeloid neoplasms. Hematology, 2022, 27, 765-771.	1.5	2
20	Comprehensive screening for coexisting heterozygous $\hat{\pm}$ 0-thalassemia in hemoglobin E trait. Hematology, 2020, 25, 276-279.	1.5	0
21	Haploinsufficiency and Deletions of G3BP1 on Chromosome 5q Result in Induction of TP53. Blood, 2014, 124, 784-784.	1.4	0
22	Genetic Mutation in Cytopenic Patients: Distinctive Genomic Profile between Preclinical Vs. Clinical Myelodysplastic Syndrome. Blood, 2019, 134, 5429-5429.	1.4	0
23	EXCELLENT PROGNOSIS OF LOW-RISK MYELOYDYSPLASTIC SYNDROMES (MDS) WITHOUT DETECTABLE MYELOID-RELATED MUTATIONS. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	0
24	Immune dysregulation in extranodal NK/T cell lymphomas: potential roles in pathogenesis and immunotherapy. Blood Research, 2021, , .	1.3	0
25	Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry. Hematology Reports, 2022, 14, 13-18.	0.8	0
26	Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes. Asian Pacific Journal of Cancer Prevention, 2021, 22, 4037-4042.	1.2	0